Browse
Submit Data
Databases
API
Help

Dataset Information

17 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Randomized phase II study of adding tramadol for prevention of venous pain in colorectal cancer patients who are receiving oxaliplatin through peripheral vein

ABSTRACT: Interventions: oxaliplatin 130mg/m2 day1 oral 5FU 80-120mg/m2 day1-14 every 3weeks Tramadol is given orally at a dose of 25mg once a day starting on the day of oxaliplatin infusion. Primary outcome(s): VRS improvement rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2633365 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Randomized phase II study of adding steroid for prevention of venous pain in colorectal cancer patients who are receiving oxaliplatin through peripheral vein (APOLLO)

Project description:Interventions: XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Oxaliplatin is combined with dexamethasone (2 mg). XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Primary outcome(s): The incidence of venous pain:Grade>=2 Study Design: Parallel Randomized

| 2619736 | ecrin-mdr-crc

The randomized phaseII study of SOX and SIR sequential therapy as TS-1 based regimens in Advanced Colorectal Cancer; WSTAR trial

Project description:Interventions: 1st line chemotheraypy: SOX+Bmab Bmab: 7.5mg/kg every 3weeks L-OHP: 130mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 2nd line chemotheraypy: SIR+Bmab Bmab: 7.5mg/kg every 3weeks CPT-11: 150mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 2nd line chemotherapy: choose either (did not use by) 1)SIR+Bmab Bmab: 7.5mg/kg every 3 weeks CPT-11: 150mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7 days off 21st 1 course. 2) SIR+Cmab Cmab: 250mg/m2 every week CPT-11: 150mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 3)SIR+Pmab Pmab: 6mg/kg every 2 weeks CPT-11: 150mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course 4)SIR CPT-11: 150mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7 days off 21st 1 course. 5)SOX+Bmab Bmab: 7.5mg/kg every 3 weeks L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7 days off 21st 1 course. 6)SOX+Cmab Cmab: 250mg/m2 every 2 weeks L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 7)SOX+Pmab Pmab: 6mg/kg every 2 weeks L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14 days on, 7days off 21st 1 course 8)SOX L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14 days on, 7days off 21st 1 course Primary outcome(s): Overall survival:OS Study Design: Parallel Randomized

| 2623112 | ecrin-mdr-crc

Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal cancer

Project description:Interventions: Oxaliplatin 130mg/m2 i.v.(day1) Bevacizumab 7.5mg/kg i.v.(day1) Capecitabine 2000mg/m2 p.o.(day1-14) to be repeated every 3weeks Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

| 2620414 | ecrin-mdr-crc

Phase I study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: Cetuximab 400mg/m2 Day1, 250mg/m2 Day 8, 15 Irinotecan 100-150mg/m2/Day1 S-1 80-120mg/day Day1-14 Primary outcome(s): Recommended Dose Study Design: Single arm Non-randomized

| 2626021 | ecrin-mdr-crc

Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS+Bev second-line treatment

Project description:Interventions: S-1+CPT-11+bevacizumab+Placebo S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Placebo day1-28 q4w S-1+CPT-11+bevacizumab+hange-shashin-to S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Hange-shashin-to 7.5g/day day1-28 q4w Primary outcome(s): Incidence of grade 3 or more diarrhea until the end of 3rd cycle Study Design: Parallel Randomized

| 2627635 | ecrin-mdr-crc

Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).

Project description:Interventions: Cetuximab/S-1 combination therapy Cetuximab weekly administration 400 mg/m2(day1), 250mg/m2/week(except day1) S-1 80-120mg/day, PO from day1 to day 28 of each 42 day cycle. Primary outcome(s): Progression free survival(PFS) Study Design: Single arm Non-randomized

| 2617952 | ecrin-mdr-crc

Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumab

Project description:Interventions: S-1/irinotecan combination therapy Irinotecan 100 mg/m2(day1,15), S-1 80-120mg/day, PO from day1 to day 14 of each 28 day cycle. Primary outcome(s): Progression free survival(PFS) Study Design: Single arm Non-randomized

| 2625128 | ecrin-mdr-crc

Phase II clinical trial of Cetuximab with Fluorouracil therapy for patients refractory or intolerable to Oxaliplatin and Irinotecan with KRAS wild-type unresectable/recurrent colorectal cancer

Project description:Interventions: (Cetuximab with Fluorouracil therapy) Cetuximab=400mg/m2 (day1)Cetuximab=250mg/m2/weekly(day 8-) with 1) l-LV=200mg/m2/bi-week 5-FU/bolus=400mg/m2/bi-week 5-FU/infusional=2,400mg/m2/bi-week (day1-3) 2) LV=75mg/day (*Administration for 4weeks and Drug withdrawal for one week)UFT=300-600mg/day* 3) Capecitabine=2,000mg/m2/day(*Administration for 2weeks and Drug withdrawal for one week) 4) S-1=80-120mg/day (*Administration for 2weeks and Drug withdrawal for one week) Primary outcome(s): Progression-free survival; PFS Study Design: Single arm Non-randomized

| 2623785 | ecrin-mdr-crc

Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2,000mg/m2/day day1-15 XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 200mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): ORR; Overall response rate Study Design: Parallel Randomized

| 2622964 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data